DURECT Corporation Receives FDA Breakthrough Therapy Designation For Larsucosterol In Alcohol-Associated Hepatitis
DURECT Corporation Receives FDA Breakthrough Therapy Designation For Larsucosterol In Alcohol-Associated Hepatitis
DURECT公司获得美国食品药品管理局对Larsucosterol治疗酒精相关性肝炎的突破性疗法认定
DURECT Corporation Receives FDA Breakthrough Therapy Designation For Larsucosterol In Alcohol-Associated Hepatitis
DURECT公司获得美国食品药品管理局对Larsucosterol治疗酒精相关性肝炎的突破性疗法认定
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。